Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years-Reference-Cited by-同舟云学术

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years

Published:2014-02-02 Issue:10 Volume:33 Page:1433-1441
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Kingsbury Daniel J.,Bader-Meunier Brigitte,Patel Gina,Arora Vipin,Kalabic Jasmina,Kupper Hartmut

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-014-2498-1.pdf

Reference22 articles.

1. Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369:767–778

2. Cassidy JT, Petty RE (2001) Textbook of pediatric rheumatology, 4th edn. WB Saunders Company, Philadelphia

3. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392

4. Humira [Prescribing Information, Japan]. Abbott Japan Co., Ltd. Mita, Minato-Ku, Tokyo. (Accessed 07 February 2013, at http://www.info.pmda.go.jp/go/pack/3999426G1024_1_15/ )

5. Humira [Prescribing Information]. AbbVie Inc. 2012. (Accessed 07 February 2013, at http://www.rxabbvie.com/pdf/humira.pdf )

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Overview of Adalimumab Therapy for Ankylosing Spondylitis;Current Rheumatology Reviews;2024-12

2. Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data;Pediatric Drugs;2024-04-17

3. Adverse events of biological agents in pediatric rheumatologic diseases;Postgraduate Medicine;2024-02-17

4. Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases;Pediatric Rheumatology;2024-01-02

5. Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment;Pediatric Rheumatology;2023-12-20